BLOG

2020 has been quite a year! Each year, we strive to provide you with a more innovative, simplified, and seamless early phase drug development journey. And the past 12 months have been no exception.

Hallucinogens, dissociatives and other Schedule I drugs are increasingly being found to have a clinical application in a number of therapeutic areas. Recent approvals, background, and related case studies in this month's blog.

The formulation of an active pharmaceutical ingredient (API) to ensure maximum bioavailability is central to successful drug development. When an API is insoluble or poorly soluble, it will require processing...

The FDA guidance specific to COVID-19 vaccines has some differences, and some commonalities, with current vaccine guidance. This blog and related podcast provide insight.

Ensuring that current and relevant FDA and EMA guidances are applied to the handling of bioanalytical samples during clinical trial conduct is crucial. This month's blog, including podcast, offers an expert look at the considerations.

The development of pharmaceutical products, in dosage forms that the human body can safely and effectively metabolize, is a challenging undertaking. In this month's blog, we offer insight on the process, and a related podcast featuring our CDMO experts.

As the COVID-19 pandemic evolves across the globe, the search for effective therapies also continues to gain momentum, including the possibility of repurposing existing medications that may show effectiveness against COVID-19 symptoms.